618 results on '"Zaia, John A."'
Search Results
2. COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins.
3. Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells
4. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants
5. CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges.
6. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation
7. Recurrent SARS-CoV-2 mutations at Spike D796 evade antibodies from pre-Omicron convalescent and vaccinated subjects
8. 314 Development of bi-specific chimeric antigen receptor (CAR) T cell therapy for the treatment of AIDS-related B cell malignancies
9. Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation
10. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
11. How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation
12. A Nucleolar TAR Decoy Inhibitor of HIV-1 Replication
13. Prevention of Cytomegalovirus Disease in Hematopoietic Stem Cell Transplantation
14. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults
15. Supplementary Table 1 from CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
16. Supplementary Figure S4 from CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
17. Supplementary Tables 1-5 from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010
18. Supplementary References from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010
19. Data from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010
20. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial
21. Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient
22. Autotransplantatie na heftig trauma: Keuzes maken en samenwerken
23. Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adults
24. Role of Nursing Competencies for Accelerating Clinical Trials in Stem Cell Clinics
25. Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine
26. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
27. Hematopoietic Cell Transplantation with Cord Blood for Cure of HIV Infections
28. Erratum: Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant
29. Advances in CMV Diagnostic Testing and Their Implications for the Management of CMV Infection in Transplant Recipients
30. Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant
31. Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation
32. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity
33. Putative Protective Role of Sars-Cov-2-Specific T Cells in an HCT Patient Transplanted during Active COVID19 Infection
34. COVID-19 vaccination recruits and matures cross-reactive antibodies to conserved epitopes in endemic coronavirus Spike proteins
35. Large-scale manufacturing and characterization of CMV-CD19CAR T cells
36. Viral Infections in Organ Transplant Recipients
37. Prophylaxis and Treatment of CMV Infections in Transplantation
38. Expression of Activating KIR2DS2 and KIR2DS4 Genes after Hematopoietic Cell Transplantation: Relevance to Cytomegalovirus Infection
39. Functional Comparison of T Cells Recognizing Cytomegalovirus pp65 and Intermediate-Early Antigen Polypeptides in Hematopoietic Stem-Cell Transplant and Solid Organ Transplant Recipients
40. Practical Considerations in Gene Therapy for HIV Cure
41. Simultaneous Reconstitution of Multiple Cytomegalovirus-Specific CD8⁺ Cell Populations with Divergent Functionality in Hematopoietic Stem-Cell Transplant Recipients
42. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study
43. HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma (NHL)
44. Antiviral Evaluation of HIV-1 Specific Ribozyme Expressed in CD4+ HeLa Cells
45. Human Immunodeficiency Virus-Infected Patients Receiving Highly Active Antiretroviral Therapy Maintain Activated CD8⁺ T Cell Subsets as a Strong Adaptive Immune Response to Cytomegalovirus
46. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients
47. Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
48. The Effect of Single and Combined Activating Killer Immunoglobulin-like Receptor Genotypes on Cytomegalovirus Infection and Immunity after Hematopoietic Cell Transplantation
49. Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy
50. Cloning and Physical Mapping of a Gene Fragment Coding for a 64-Kilodalton Major Late Antigen of Human Cytomegalovirus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.